Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Dermatologic 3CNS 3Lymphoid 2Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Sarcoma 32Melanoma 10Osteosarcoma 8Neoplasm Metastasis 8Sarcoma, Kaposi 6Leiomyosarcoma 6Histiocytoma, Malignant Fibrous 6Chordoma 6Gliosarcoma 5Colorectal Neoplasms 5Carcinosarcoma 5Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Sarcoma, Ewing 4Neuroblastoma 4Neoplasms 4Bone Neoplasms 4Rhabdomyosarcoma 3Neurofibrosarcoma 3Lung Neoplasms 3Hemangiosarcoma 3Glioblastoma 3Gastrointestinal Stromal Tumors 3Endometrial Neoplasms 3Desmoid Tumors 3Cholangiocarcinoma 3

Interventions

Vincristine 25Cyclophosphamide 25Irinotecan 21Temozolomide 18Doxorubicin 16Radiotherapy 15Filgrastim 15Ifosfamide 14Dactinomycin 14Etoposide 11Vinorelbine 9Melphalan 9Magnetic Resonance Spectroscopy 9Granulocyte Colony-Stimulating Factor 9Radiation 8pegfilgrastim 7X-Rays 7Specimen Handling 7Sirolimus 7Topotecan 6Phantoms, Imaging 6Peripheral Blood Stem Cell Transplantation 6Gemcitabine 6cixutumumab 5Busulfan 5Biopsy 5temsirolimus 4irinotecan sucrosofate 4fludarabine 4etoposide phosphate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Nivolumab × Sarcoma × Clear all
NCT05302921 2025-01-01

Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors

Children's National Research Institute

Phase 2 Completed
5 enrolled
CNSDermatologicGastrointestinalGenitourinarySarcoma

Carcinoma, Hepatocellular, Melanoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma

NCT02304458 2023-10-17

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

National Cancer Institute (NCI)

Phase 1/2 Completed
140 enrolled 23 charts
CNSDermatologicLymphoidSarcoma

Hodgkin Disease, Lymphoma, Non-Hodgkin, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT04730349 2023-03-24

PIVOT IO 020

Bristol-Myers Squibb

Phase 1/2 Terminated
15 enrolled 14 charts
CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡